Analysis of U.S. Food and Drug Administration Draft Guidance on Clinical Trials with Psychedelic Drugs
Healthcare Law Insights blog
JUNE 30, 2023
Dr. Tiffany Farchione, director of FDA’s Division of Psychiatry in the Center for Drug Evaluation and Research (CDER), recognized that psychedelic drugs show initial promise, but that they are still investigational products with unique characteristics that should be considered when designing clinical studies.
52 
Let's personalize your content